Hanson Pharmaceuticals (03692): HS-20197 for injectable use received a notice of approval for clinical trials of drugs issued by the State Drug Administration

According to Zhitong Finance App, Hanson Pharmaceuticals (03692) issued an announcement. On September 11, 2026, HS-20197, a Class 1 new drug independently developed by the Group received a drug clinical trial approval notice issued by the China National Drug Administration (NMPA) to carry out clinical trials of “advanced solid tumors”.